- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
HHS to Fund Regeneron's Efforts for Antibody Against Ebola
The collaboration will make available 3 fully-humanized monoclonal antibodies to fight the devastating virus.
The US Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response has entered into an agreement with Tarrytown-based Regeneron Pharmaceuticals, Inc to develop a treatment regimen that includes 3 monoclonal antibodies against the Ebola virus.
The company has developed the 3 fully-humanized monclonal antibodies using their propreitory VelociGene and VelocImmune technologies, and will receive $38 million over a 2-year period for further development and manufacturing of the monoclonal antibodies.
Read the associated press release by HHS here.
Study Suggests Adding BTKi to Chemo May Improve Early Outcomes in Richter Transformation in CLL
December 18th 2025The study suggests that adding a Bruton tyrosine kinase inhibitor (BTKi) to frontline chemoimmunotherapy in Richter transformation improved complete response rates and progression-free survival compared with chemoimmunotherapy alone, though overall survival benefits remained unclear.
Read More
